Tag Archives: economy

10 Best Mutual Funds For The Next Decade From 10 Investment Strategists

Summary Aging demographics, rising demand for less invasive ways to stay active or better address illnesses, emerging market growth of healthcare demands and real products are bullish for Fidelity Select Biotechnology. Parnassus Endeavor has outperformed the S&P 500 by 4.8% annually over the past 10 years. In addition to removing alcohol, tobacco, gambling, firearms and nuclear power from the portfolio. China’s P/E ratio is 8.7 times the next 12 month’s forecast earnings by analysts, which is below the past five years’ average, and a little more than half the U.S. Investors are understandably worried about their portfolios in light of the stock market selloff in August and September. But in the long run, a 10% or even 20% correction will be merely a blip on the screen. To help you focus on the long term, I asked a panel of investing strategists to share their mutual fund investing idea that they have conviction in for the next decade. 1. Fidelity Select Biotechnology Portfolio (MUTF: FBIOX ) By Jim Lowell Aging demographics, rising demand for less invasive ways to stay active or better address illnesses, emerging market growth of healthcare demands, real products, real earnings, and time-tested management are all part of my positive diagnosis for investing in biotechnology and healthcare stocks. For the aggressive growth investor, I recommend Fidelity Select Biotechnology. Priced to perfection and prone to price-related swoons, this sector remains one of my absolute long-term buy recommendations. After the recent price gouging biotech brouhaha, many blue-chip biotechs were being sold down as if they were in the same boat as the upstart Turing Pharmaceuticals, whose capitalist instincts ran away with its better nature, raising the price of a niche but necessary drug from $13.50 to $750 a dose. The CEO finally buckled to public relations pressure and announced that the company would lower the price of the drug in response to the outcry. Of course, Biogen-Idec (NASDAQ: BIIB ), Gilead (NASDAQ: GILD ) and others have diversified portfolios of efficacious biotech drugs and are a far cry from the Turing’s one-trick pony. There will be other blowups under the biotech tent, making it a natural place for proven active management to take center stage. As an individual investor, I’d be nervous about trying to time into this sector as well as pick a broad array of biotech stocks that could reduce near-term risks and enhance long-term return. By investing in FBIOX, I don’t have to worry about either, since manager Rajiv Kaul does that job for me. Currently, his top holdings are Gilead Sciences, Biogen, Alexion (NASDAQ: ALXN ), Celgene (NASDAQ: CELG ), Regeneron (NASDAQ: REGN ), Vertex Pharmaceuticals (NASDAQ: VRTX ), BioMarin Pharmaceutical (NASDAQ: BMRN ), Medivation (NASDAQ: MDVN ), and Incyte (NASDAQ: INCY ). FBIOX is up 13.8% year-to-date through September 23. For the defensive growth investor, I recommend the Fidelity Select Health Care Portfolio (MUTF: FSPHX ). Top-ranked manager Eddie Yoon invests in companies involved in the design, production, or sale of health care products and services, including, but not limited to: pharmaceutical, diagnostic, administrative, medical supply, and biotechnology companies. This sector represents 17% of U.S. GDP and covers thousands of stocks and experimental drugs. You can’t bring the acumen, informed insight and trade execution capacity and quality to this field, but Yoon can and does. He invests with an eye on the necessary demographic trends and stories of aging boomers needing a youth-inducing crutch as well as on the emerging market theme of new consumers demanding better healthcare. His current top holdings include Boston Scientific (NYSE: BSX ), Teva (NYSE: TEVA ), Abbvie (NYSE: ABBV ), McKesson (NYSE: MCK ), Vertex, UnitedHealth (NYSE: UNH ), Shire (NASDAQ: SHPG ), and Bristol-Myers Squibb (NYSE: BMY ). While sub-sectors like biotechnology have been blazing higher, there are other defensive sectors when higher alpha plays are being sold off. One stealth benefit: This is a globally diversified sector with this fund’s foreign investments typically making up one-third of its assets. Jim Lowell is editor of FidelityInvestor.com and chief investment officer at Adviser Investments with $3 billion under management in Newton, Mass. He owns both funds mentioned here. 2. Deutsche Bank Global Infrastructure Fund ( TOLSX ) By Jeremy S. Office, Ph.D., CFP, CIMA, ChFC, CRPC, MBA We believe one of the best opportunities for investors with more than a seven-year time horizon is global infrastructure. According to the World Economic Forum, global infrastructure demand is approximately $4 trillion annually with only $2.7 trillion invested each year. Global infrastructure remains underdeveloped, and existing structures are in their later stages of life. As government balance sheets near their tipping point, we believe this gap will open the doors for private investment opportunities that will further attract investors into the asset class. Also, the potential to hedge inflation by investing in companies with the ability to raise prices (high pricing power) may also be attractive if inflation begins to increase. At Maclendon, we use the Deutsche Bank’s Global Infrastructure Fund as a diversified way of investing in this vertical. Although the world may be slowing down economically, population growth and the need for updated infrastructure remain high. With the essential need of infrastructure within a society, the resiliency of cash flows, and the potential hedge against inflation, we believe this to be a compelling investment in a portfolio over the next 10 years. The current zero interest rate policy has diminishing value to stimulate the economy and eventually leads to asset bubbles that could jeopardize the entire experiment in the first place. Cutting interest rates and embarking on quantitative easing to stimulate the economy was necessary during the financial crisis, but we have made considerable progress since and believe a Fed rate hike in September was warranted. We understand the global implications of higher rates and how the Fed is attempting to accomplish a “Goldilocks” raise, not too much and not too soon, but believe at this point we need to move off zero at least for the reason of having the ability to lower them again if markets do show further signs of weakness. Right now the Fed has used all of their tools in its toolbox. If the economy cannot withstand a 0.25% hike in rates, we are in worse shape than previously thought. There is a misconception with retail investors that higher interest rates are bad for the economy, but when you are coming off zero that doesn’t hold true. Higher rates could stimulate the economy as banks are more inclined to lend, retirees are earning more on their fixed income, and would be homebuyers get off the sidelines to avoid higher mortgage rates. Jeremy S. Office, Ph.D., CFP, CIMA, ChFC, CRPC, MBA, is founder and principal of Maclendon Wealth Management in Delray Beach, Fla. with $140 million under management. 3. DFA Global Allocation 60/40 Portfolio (MUTF: DGSIX ) By Michael S. Brown CFA, CPA, CFP® Over the last six weeks, U.S. large-cap stocks have declined by 10%, erasing year-to-date gains. Times like these are healthy because they remind investors that the stock market’s attractive historical returns do not come without risk. Successful long-term investors understand that strong equity markets are inevitably followed by downturns, the timing and magnitude of which are impossible to predict. They specifically demonstrate discipline by avoiding the herd mentality and taking advantage of occasions when stocks are priced most competitively. Dowling & Yahnke aims to build highly diversified portfolios that align with client risk tolerance and long-term investment objectives. Combining this philosophy with a mandate to minimize costs, manage taxes and rebalance in a disciplined manner limits the scope of funds with which we place client assets. When recommending a solution for an investor with a moderate risk tolerance and long-term investment horizon, DFA’s Global Allocation 60/40 Portfolio is a great choice. While many all-in-one fund options exist, DGSIX delivers DFA’s unique investment approach in an efficient, low-cost package. The portfolio, which features a globally diversified fund-of-funds structure with built-in rebalancing, is designed to seek total returns consisting of capital appreciation and current income by investing 60% of assets in equity funds and 40% in fixed income funds. The funds included in the Global Allocation 60/40 Portfolio provide broad exposure to global markets, including more than 10,000 securities in more than 40 countries at a low net expense ratio of 0.29%. In addition to providing an allocation to inflation-protected securities, the equity components of DGSIX employ Dimensional’s applied core equity approach, emphasizing smaller cap, relatively low price, and higher profitability stocks to enhance expected returns. The fixed-income components complement the equity allocation, helping to optimize the tradeoff between dampening risk and maximizing expected return. Michael S. Brown CFA, CPA, CFP® is a partner at Dowling & Yahnke, LLC in San Diego, Calif. with $3 billion under management. 4. Parnassus Endeavor Fund (MUTF: PARWX ) By Michael Kramer Parnassus Endeavor is a $1.3 billion large-cap core mutual fund with a five-year annual return of 14.8% and a 10-year annual return of 11.2% through September 30, 2015. This fund has outperformed the S&P 500 by 4.8% annually over the past 10 years. In addition to removing alcohol, tobacco, gambling, firearms and nuclear power from the portfolio, it also seeks out sector leaders in areas such as community relations, labor standards, human rights, environmentally-friendly practices, and employee health, safety, diversity, and rights. Research has long indicated that ESG integration has a neutral-to-positive correlation to long-term financial performance. In volatile and uncertain markets, investors that view ESG factors as material to bottom-line performance understand that true long-term profitability is directly connected to adherence to best corporate practices around risk mitigation. This low-turnover fund overweights technology and financial services while emphasizing dividend-yielding positions and, at 39%, has twice the benchmark and category averages of mid-cap stocks. Top holdings include Altera (NASDAQ: ALTR ), Intel (NASDAQ: INTC ), Whole Foods Market (NASDAQ: WFM ), American Express (NYSE: AXP ), Applied Materials (NASDAQ: AMAT ), and IBM (NYSE: IBM ), representing 35% of the portfolio weight. This fund has been resilient in down-markets and strong in growth periods. During the 2008 downturn, for example, the fund was down 30%, while the S&P 500 lost 38% of its value, and in 2009 the fund was up 62%, while the S&P was up only 26%. Manager Jerome Dodson, who founded Parnassus Investments in 1984 and has managed this fund for 11 years, maintains a consistent and disciplined approach, which has helped this sustainable and responsible fund to earn 5 stars from Morningstar and place in the top 1% of all mutual funds for 10-year tax-adjusted return in its category. Michael Kramer is managing partner and director of social research at Natural Investments and co-author of The Resilient Investor: A Plan for Your Life, Not Just Your Money. 5. Federated Global Allocation Fund (MUTF: FSTBX ) By Stephen F. Auth, CFA Federated Global Allocation Fund is a diversified global balanced fund that can go anywhere and has sufficient flexibility to preserve capital in market corrections, while also being able to participate significantly in the secular bull that we believe we are in. It goes without saying: It’s been a rather messy time for stocks. The China fears that sparked this summer’s sell-off have been succeeded by handwringing over what the Fed sees that’s keeping it from liftoff. Don’t expect clarity anytime soon. No major upside surprises appear to be lurking on the economic calendar, and we are entering what historically has been an unsettling seasonal period. We see recent market volatility continuing for the next several weeks, with a likely retest of August’s lows, i.e., an S&P 500 that trades 3% to 5% below present levels. Over the longer term, however, we remain “stubbornly constructive” on equities. Secular bull markets such as we are in occasionally experience corrections that wash out the weak hands and set the stage for the next advance. This is what we are currently experiencing. The list of positive drivers off current levels is long and more in place than ever: Negative sentiment regarding stocks. Highly accommodative global monetary policies. Low global inflation. Low global yields. An expanding global economy despite headwinds from China. Corporate balance sheets and cash flows that remain very healthy. Valuations that are attractive and not expensive, price-to-earnings multiples are below 15 times expected 2016 S&P earnings of $130 to $135. We think this market will find new legs later this year into next and have not changed our 2,500 S&P target for 2016, implying close to a 30% upside from the present. With the market currently selling almost indiscriminately, we favor oversold stocks in such areas as domestic cyclical, consumer discretionary, financials, healthcare/biotech, even rate-sensitive utilities, and staples. We still think it’s too early to buy into energy and industrial and commodity names with big overseas exposure. People ask me, “What will be the catalyst?” My answer: When you have corrections like this, with babies being thrown out with the bathwater and companies with fantastic multi-year fundamentals like many of the health-care stocks being sold hard and indiscriminately by the ETF providers, you don’t need any of the positive catalysts listed above to spark a sustained rally. You just need a few things to get less worse, in particular news out of China. Once the market sniffs out this “less-worse” scenario, perhaps late in the fourth quarter, look out above. Stephen F. Auth, CFA is chief investment officer of equities at Federated Investors, Inc. Pittsburgh, Penn. with $349.7 billion under management. 6. Cognios Market Neutral Large-Cap Fund (MUTF: COGMX ) By Jonathan Angrist Investors should consider alternative mutual fund strategies as a diversification tool for their portfolios with a particular focus on those strategies that hedge market exposure. Market neutral equity is one of the few strategies that actually moves independently of the stock and bond markets, offering true diversification. Why is additional diversification necessary? We see the gulf between attractively valued companies with good long-term growth prospects and over-valued companies with challenging growth opportunities to be very wide, diminishing the potential for returns from traditional equity markets. Further, the current interest rate environment creates additional hurdles for traditional asset allocation. Rates will rise, and when they do increased rates are likely to impact both the equity and fixed income markets. This is likely to challenge traditional long-only strategies, but creates an opportunity for market neutral strategies. Due to the cyclicality of earnings, the Shiller cyclically-adjusted price-to-earnings ratio (NYSEARCA: CAPE ) is often used as a more accurate indicator of long-term earnings power than unadjusted earnings per share. As of August 31, 2015, this ratio stood at 25.84 times. Historically, when this ratio rises above 25.0 times, our research shows that the annualized return for the Standard & Poor’s 500 Index (S&P 500) is near zero for the following five years. Even with the continued economic expansion, we expect corporate profits to decline given that corporate profits as a share of gross domestic product are near all-time highs. As a result of continuing quantitative easing in Europe, on-going quantitative easing in Japan and slowing economic growth in China, earnings from foreign countries are also likely to decline due to the strengthening U.S. dollar. Conditions in the fixed income market are difficult as well. Many members of the Federal Open Market Committee have indicated that they would like to raise the federal funds rate by 0.25 percent before 2015 year-end. Barring further intervention long-term rates are also likely to rise. Long-term Treasury rates will continue to rise as China and commodity-dependent nations liquidate foreign currency reserves to stabilize their own currencies and plug national deficits. The potential for disappointing future performance of traditional asset classes and the increased market volatility, economic uncertainty and geopolitical turbulence that continues to persist highlights the need for a market neutral allocation in a well-balanced and diversified portfolio. Market neutral strategies offer the opportunity for returns that are independent of broad market and macro events. Jonathan Angrist is president and chief investment officer of Cognios Capital in Leawood, Kan. with $329 million under management. 7. AQR Risk Parity II MV Fund (MUTF: QRMIX ) By James F. Smigiel For many investors, a 10-year time horizon can be liberating in terms of the types of riskier investment opportunities that would not be viable over shorter time frames. There is a tendency among investors to view risk differently as holding periods lengthen. Specifically, the risk tolerance of the typical investor tends to increase as the period expands. Perhaps this stems from the fact that there are some statistical measures of risk that tend to decrease as the period increases. Whatever the reason, the investment community has not served these investors well, as there is still a surprising amount of controversy and confusion about the relationship between time and risk. SEI believes the facts are clear and investors should recognize that the range of potential outcomes, both positive and negative, will expand as time horizon increases. This is a natural result of returns compounding over time. In other words, the longer the time horizon, the greater amount of uncertainty. Given the above, SEI’s recommendation for the next 10 years would be a highly diversified investment that could be expected to perform relatively well in many potential economic and market scenarios. Specifically, we would suggest any of the so-called “Risk Parity” mutual funds including AQR Risk Parity II MV I or the SEI Multi-Asset Accumulation Fund (MUTF: SAAAX ). These funds and others like them provide investors with equal or near-equal exposures to multiple asset classes such as global equities, global bonds and global inflation-related assets (inflation-linked bonds, commodities). Unlike traditional balanced funds, however, these portfolios balance asset classes by risk contribution as opposed to a percentage of assets invested. Investing across asset classes via the amount of dollars invested can leave a portfolio highly concentrated in one exposure given the wide differences in asset class volatilities (i.e. equities can be more than twice as volatile as bonds). A portfolio that invests half of its dollars in stocks and half in bonds might appear diversified, but because stocks are so much riskier than bonds, nearly all of that portfolio’s risk would be contributed by stocks. Risk parity seeks to make all assets, even low-risk ones, “matter” at the overall portfolio level. An allocation approach that focuses on risk provides a truly diversified portfolio, which could be expected to perform well across a range of market and economic environments versus a more traditional, but concentrated, approach. Given the level of uncertainty that a ten-year horizon represents, we believe this choice provides the investor with the best chance of achieving a reasonable rate of return without accepting an undue amount of risk. James F. Smigiel is a managing director of Portfolio Strategies Group SEI Investment Management Unit at SEI at Oaks, Penn. with $262 billion under management. 8. Arrow Alternative Solutions Fund (MUTF: ASFNX ) By Joseph Barrato Over the next decade, we believe what is happening with the bond market may be just as relevant for investors as the direction of the stock market. Despite the Federal Reserve’s recent decision to keep interest rates unchanged, the world obviously anticipates rising rates in the future. This may mark the end to a declining rate environment that began in the 1980s. Although it’s true that we’ve experienced instances of rate hikes during the last few decades, we are now entering unchartered territory not seen by many of today’s investors. In the past when rates have increased, bond fund performance was cushioned by portfolio yields that were higher than prevailing market rates. We now have an environment where portfolio rates have slowly declined to the point where competitive yields are few and far between. Generating yield income is not the sole reason for holding bonds. Many portfolios are built to rely on fixed income as a core diversifier to offset the volatility of large equity exposure. As such, we expect to see a huge demand for non-traditional and alternative bond funds among investors who are looking either to replace or supplement their fixed income holdings with strategies that can deliver in rising and declining rate environments. The Arrow Alternative Solutions Fund is an example of a non-traditional bond fund that seeks capital appreciation with an emphasis on absolute returns and low volatility. Composed of three underlying fixed income strategies, the fund relies on quantitative analysis to optimize long/short/flat exposure to corporate high-yield bond markets, credit default markets, and long-term U.S. Treasury bond markets. As a result, the Arrow Alternative Solutions Fund has shown a low historical correlation to traditional equity and fixed income markets, and may also help to diversify an investment portfolio during various rate environments. As with any investment, investors should carefully consider risks with benefits. In this case, the Arrow Alternative Solutions Fund uses a combination of derivatives and fixed income securities to achieve its objective, which are subject to interest rate, credit, and inflation risks. Joseph Barrato, CEO and director of investment strategy at Arrow Funds in Laurel, Md. with $700 million under management. 9. Index Funds S&P 500 Equal Weight Fund (MUTF: INDEX ) By Michael G. Willis Having trouble beating the S&P 500 Index? Join the club, and it’s a large club. According to the most recent SPIVA report released by Standard & Poor’s, over 86% of large-cap fund managers could not beat it last year, and those numbers approach nearly 90% if you look at the past 5-year period. In March of 2014, Warren Buffett announced that his advice to his heirs is to put 90% of his estate in “a very low-cost S&P 500 index fund.” That’s a strong endorsement coming from arguably one of the best stock traders on the planet. So, what could be better than owning the S&P 500 Index for the next 10 years? Well, since the index is already in a class by itself, try beating the S&P 500 Index with a simple & logical version of itself! We believe one of the best-kept secrets on Wall Street is the S&P 500 Equal Weight Index. This index holds the same 500 companies with a minor twist: each of the 500 companies is held equally over time. Simple, right? This is in stark contrast to the market-cap version that uses a complex formula that winds up allocating over 50% of the portfolio to only 50 companies. It could be argued that the equal-weight version of the S&P 500 Index is the “pure” version of the index because it invests in each of the 500 companies equally, without bias. By definition, this makes it a better-diversified version of the index as it does not over-weight a select few. Incredibly, since its inception in 2003, this simple & logical version of the index has outperformed its “big brother” nine out of 12 years. Although many investors prefer index funds because of the lower costs, a key benefit of index investing is the peace of mind factor. Since no one knows the future, why second guess it or attempt to time it? An index portfolio manager’s read on current market conditions doesn’t matter, as their job is to track the index and ignore everything else. Index investors can also follow their lead here and attempt to ignore the daily “noise” on Wall Street and focus on their individual long-term goals. For 20 years, we were in the club that tried to beat the S&P 500 Index. Now this simple equal weight strategy might just have the best ticker on Wall Street: INDEX. Michael G. Willis is lead portfolio manager of The Index Group, Inc. in Colorado Springs, Colo.with $3 million under management. 10. Fidelity China Region Fund (MUTF: FHKCX ) By Kheim Do Investors have been bombarded by speculation that the Chinese economy probably already is sliding into a recession, and that it could pull the rest of the industrialized world down as well, especially at an awkward time when the U.S. Federal Reserve Board is contemplating raising interest rates. The increasing chatter of the scenario of a global recession in 2016 is a frightening one, especially when the world economy has barely started recovering from the recent financial crisis. According to some well-followed surveys of investor sentiment by global investment banks including Citigroup and Credit Suisse, the current mood is nearly as depressing as that prevailing in the dark days in the aftermath of the 2008 global financial crisis. The pricing of assets which are dependent on China’s economic growth have fallen significantly. For instance, oil prices and global emerging equity markets have fallen by 60% and 28% respectively over the past 12 months. The book of investment history suggests however that a savvy investor should act in a contrarian manner, when we are at extreme sentiment levels. In other words, the current high level of fear offers excellent long-term buying opportunities. Our global strategic policy group has regularly been monitoring and analyzing massive amounts of data, covering all the major economies around the world, ranging from weekly to 100-year data points. At the beginning of each year, a dedicated specialist team performs a detailed projection of the coming 10-year growth rate of gross domestic product in real, nominal (including inflation) and per capita terms. This, combined with the starting valuation tools, including price/earnings ratio and dividend yield, associated with each major asset class, constitutes the foundation of our 10-year total return forecasts of major bond, equity and currency markets. We are proud to report that our 10-year predictions of equity markets’ total returns made in 2004 for the decade ending 2014 turned out to be “deadly” accurate. Barings’ 10-year forecasts made at the beginning of this year suggests that the best equity market in the coming decade is China. Surprised? I expect so. As a market, China is unloved and current valuations of listed companies suggest an unduly pessimistic scenario of very little growth in nominal economic and corporate profit growth in the coming five to 10 years, while the reverse is true for the U.S. stock market, where high valuations discount a very rosy outlook. China’s price-to-earnings ratio is 8.7 times the next 12 month’s forecast earnings by broking analysts, which is significantly below the past five years’ average, and a little more than half of that of the U.S. equity market. Khiem Do is investment director at Baring Asset Management in Hong Kong with $38.7 billion under management.

The Health Care Sector’s Weakness Could Be The Investor’s Best Friend

Summary The health care sector went through a significant meltdown during the recent weeks. A long term investor might consider it as an opportunity to invest in great companies. Here is a list of 4 non-expensive ETFs that are focused on the Health Care sector. Three weeks ago a good friend of mine bought shares of Mylan Inc (NASDAQ: MYL ). His goal was to invest in a defensive stock in order to mitigate the volatile market. Since the day he made the purchase the stock was hammered down and closed is currently at a total of ~20% lower. Mylan is a global generic and specialty pharmaceuticals company that is registered in the Netherlands. In 2007, following a big acquisition Mylan became the second-largest generic and pharmaceuticals’ company in the United States. It was a wise decision at the time. Here is Mylan’s forecast P/E growth rates in the coming years based on Nasdaq.com. A P/E of 8x for a double digit growth company is not too bad at all. MYL’s stock price free fall was no different compared to other Health care companies’ stocks. If looking at the behavior of the S&P 500 Health Care Sector the graph tells us that there was about 20% drop in the sector since the recent highs. On Wednesday, September 30th, there seemed to be some recovery after several bloody weeks. (click to enlarge) The drop is explained by Hillary Clinton’s ” price gouging ” tweet which led to concerns within the investors’ community regarding higher regulations on drug pricing. Is this massive drop justified or is it an out-of-panic oversell and therefore a great opportunity? Why do I think it is an oversell? Several reasons lead me to believe it is an extreme reaction over nothing and it is a temporary meltdown: The market is very volatile in the recent weeks and it seems that the focus is only on the bad news that are being a catalyst towards a dipper correction. Back in August it was the less-than-expected growth in China’s economy, than it was the Volkswagen ( OTCQX:VLKAY ) scandal and now it is this tweet. Any regulation would need to pass Congress where the Republicans still have the major votes. It would be at least couple of years until something would really change. Not all companies are taking outrages profits on their developed drugs. The amount of Research and Development the companies are investing is huge and therefore the economy of the business will eventually dictate the prices. It will not be the politicians. The sector is composed from different types of companies. Some develop an original medicine or drug and there are generic drug companies. Some are focused on specific niches and others have huge diversification. Even if there will be new regulations not all will suffer equally. Some would even benefit from it. For those, like me, who think that it is the later here are some ETFs that invest in this sector and should be profoundly examined by the long term investor. Why an ETF and not specific stock picking? While both the uncertainty and the volatility are high an investment in a specific sector can be better managed through an ETF. In cases where an investor would like to build a position that is composed by wide list of holdings, sometimes in several steps, an ETF would be a better way to do it. Buying into a sector’s ETF allows to build a position in a by-step model. Another reason to prefer an ETF is the level of familiarity with the list of companies in the sector. Though all the sector’s companies were hurt by the recent selloff most of the investors will not know which of the companies are best to recover and which could be impacted by new regulations (in case it is not just a hot balloon towards election). An ETF allows to have a wide exposure and by that increase the probability to ride the right companies towards recovery. When looking at the list of Health care ETFs I found a list of 38 ETFs. The full list can be found here . Some of the ETFs are focused on the traditional big health care companies like Johnson & Johnson (NYSE: JNJ ), Gilead (NASDAQ: GILD ) and Pfizer (NYSE: PFE ). Others are focused on biotechnology companies like BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) and Biogen Inc. (NASDAQ: BIIB ). Some are focused on health care equipment companies and some in small biotech small startups. An investor can decide based on his or her risk profile the best ETF that suits his or her needs based on its mix and focus. Filtering the list As I like to start a list filtering by eliminating ETF that charge high management fees I have sorted out all ETFs that charge more that 0.3% per year. Surprisingly I was left with only four ETFs. (click to enlarge) The last four are: The Health Care Select Sect SPDR ETF (NYSEARCA: XLV ), which replicates Health Care Select Sector Index. The Vanguard Health Care ETF (NYSEARCA: VHT ), which replicates MSCI US Investable Market Health Care 25/50 Index. The Fidelity MSCI Health Care Index ETF (NYSEARCA: FHLC ) that replicates MSCI USA IMI Health Care Index. The PowerShares S&P SmallCap Health Care Portfolio ETF (NASDAQ: PSCH ) which replicate S&P SmallCap 600 Health Care Index. This list allows an investor to pick an inexpensive ETF based on his or her own risk tolerance. A quick comparison between the four: In term of performance, PSCH delivered the highest return in the last five years due to its more risky nature. Surprisingly it wasn’t harmed harder than the others during the recent month drop. Both XLV and VHT are tending towards the large cap health care companies. XLV seems to be more conservative as it shown by its average 18x P/E ratio versus the average of 32x. VHT has a significantly higher amount of holdings which are mostly small and medium cap companies that are trading at higher P/Es compared to the JNJs and PFEs. Conclusions: The list of four non-expensive ETFs can be examined by a long term investor who believes that the Health Care sector’s meltdown is only a temporary one. In term of the potential of long term gains, some would prefer the small cap ETF, PSCH. If looking for high diversification, VHT seems to be the best one. I picked XLV in term of risk/return tradeoff. I prefer an exposure to the big and strong companies of the sector. In any case, I suggest to plan a strategy of building a position in multiple steps. The volatility is still here and the correction can be dipper than anyone anticipates. Happy investing.

How Long Can You Stick With Failing Factor Investing?

Someone asked me the other day why I reject factor investing. My answer was simple. I said that factor investing is usually just a good marketing pitch to charge higher fees for something that will give you most of the correlation of a market cap weighted portfolio. For the uninitiated, factor investing is one of the hot buzz words in portfolio construction these days. Researchers found that “risk” doesn’t properly describe what drives returns over the long-term and several other factors were discovered that explain some of these outperforming anomalies. For instance, value stocks tend to outperform and momentum stocks often outperform. But this isn’t always the case. This is simply the case inside of the rather small data set that researchers have mined so far. And that brings us to a rather gigantic problem with factor investing: these factors can go through extremely long periods of underperformance. Eddy Elfenbein does the legwork over at Crossing Wall Street where he shows that value has underperformed the S&P 500 for 8 years. That’s an entire market cycle! I’m not sure there’s a single investor who would put up with that type of underperformance. And yet factor investing is more popular than ever. In fact, we keep coming up with new factors by the day. And when one fails we move on to some other fancier and more intricate sounding sales pitch. But here’s the really big problem for me. When you buy stocks you shouldn’t look for the absolute best portfolio. There are no holy grails. You are just looking for an adequate portfolio that reflects a very broadly diversified set of equity instruments. You don’t need the best return. You want most of the return. But most factor portfolios just increase tax and fee frictions while giving you a substantial amount of the equity correlation that you’re looking for in a portfolio. But what we find with all of these factor funds is that they’re still very highly correlated with their benchmark. If you can decide when that correlation shifts a tiny bit to give you some slice of outperformance then you’re much smarter than me and everyone else in this business. Here’s a simple example of what I mean here. If we look at growth relative to the market cap weighted portfolio we find that the two portfolios have a 96% correlation over the last 15 years: In the early 2000’s growth looked terrible relative to market cap weighting. And then it has dramatically outperformed since the financial crisis. But over the course of the entire cycle there’s no telling where you would have gotten on and off that roller coaster ride. All we know is that you got 96% of the equity market correlation. And if you jumped on the growth roller coaster you paid a higher fee and you MAYBE outperformed. So, when you start looking for that holy grail in the factor pool you really start doing two things that are cardinal sins in the world of indexing: You’re relying on being able to time when a factor will or won’t outperform. You’re increasing your fees in the pursuit of beating the market. Breaking those rules just don’t make a lot of sense to me. I prefer to keep things simple. So, maybe I am too hard on the factor investing crowd, but I just don’t see why we should pay extra for something that might give you better performance, will definitely give you most of the correlation and will definitely increase your fees. Share this article with a colleague